By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 DNA Way

South San Francisco  California  94080-4990  U.S.A.
Phone: 650-225-1000 Fax: 650-225-6000

Since 2005, Genentech has been expanding its facilities in Oceanside, about 35 miles north of San Diego. Today, the campus spans 60 acres and includes a multi-product, biotech manufacturing and clinical operations complex with six buildings totaling 500,000 square feet. Upon receiving U.S. Food and Drug Administration licensure in 2007, the Oceanside facility added 90,000 liters of capacity that are now approved for the production of Rituxan and Avastin bulk drug substance.

On the Southern California Coast, halfway between Los Angeles and San Diego, Oceanside is a beautiful beachfront community of roughly 200,000 people. As one of Oceanside’s largest employers, Genentech takes great pride in the impact we have on the community, but also in the impact the community has on our employees.

Please view our company video on YouTube:

Connect with us via Social Media:




Key Statistics

Ownership: Subsidiary

Web Site: Genentech
Employees: 10,000+
Symbol: RHHBY



Company News
Genentech (RHHBY) Opens New Bay Area Green Building to House Up to 1,500 Workers 5/21/2015 5:08:11 PM
Genentech (RHHBY)’s Investigational Immunotherapy MPDL3280A Doubled The Likelihood Of Survival Compared With Chemotherapy In People With A Specific Type Of Lung Cancer 5/14/2015 8:08:32 AM
Three Former Genentech (RHHBY) Researchers Launch Neuroscience Company Denali Therapeutics With $217 Million 5/14/2015 6:27:58 AM
Genentech (RHHBY)’s Investigational Medicine Alectinib Shrank Tumors In Nearly Half Of People With Specific Type Of Lung Cancer 5/14/2015 5:57:51 AM
Genentech (RHHBY) Lung Cancer Treatments Shrink Tumors, Prolong Life 5/14/2015 5:55:45 AM
BioSpace (DHX) Temperature Poll: Will AbbVie (ABBV), Genentech (RHHBY)’s New Cancer Drug Be a Game Changer? 5/13/2015 11:15:01 AM
Pivotal Data For Genentech (RHHBY) Medicines In Lung And Blood Cancers To Be Presented At ASCO 5/11/2015 9:15:05 AM
Genentech (RHHBY)’s Carol Wells Recipient Of The HBA’s Star Award 5/11/2015 8:59:11 AM
AbbVie (ABBV) And Genentech (RHHBY) Release: Investigational Medicine Venetoclax Receives Breakthrough Therapy Designation In Relapsed Or Refractory Chronic Lymphocytic Leukemia In Previously Treated Patients With The 17p Deletion Genetic Mutation 5/7/2015 6:42:57 AM
AbbVie (ABBV), Genentech (RHHBY) Leukemia Drug Wins Breakthrough Status Tag 5/7/2015 6:40:50 AM